Phys Vivas · rheumatological
Drug Induced Rheumatological Disease AND Biologics Safety — Viva Defence
DCE viva defence for Drug Induced Rheumatological Disease AND Biologics Safety.
On this page
Study tools
Target exams
Drug Induced Rheumatological Disease AND Biologics Safety Viva
Long Case Viva Defence
Opening statement
"This patient presents with a problem best framed as Drug Induced Rheumatological Disease AND Biologics Safety. My priorities are to identify red flags, confirm the mechanism with purposeful investigations, start a sequenced management plan, and integrate multimorbidity and follow-up." [1] [2]
Examiner questions
Q1: "What makes this urgent?" [1]
"I look for threats to airway, perfusion, neurology, metabolism, infection or bleeding, and I escalate those before elective work-up." [1] [2]
Q2: "What is your first investigation package?" [2]
"I order tests that change management now, not a scattergun panel." [1] [2]
Q3: "Walk me through treatment." [1]
"Stabilise, treat the mechanism, prevent complications, and plan monitoring." [1] [2] [3]
Q4: "What is the classic trap?" [2]
"Treating a label without confirming the discriminating mechanism, or delaying escalation." [1] [2]
References3ShowHide
- [1]Borchers AT, Keen CL, Gershwin ME Drug-induced lupus Ann N Y Acad Sci, 2007.PMID 17893983
- [2]Johnson DB, Balko JM, Compton ML, et al. Fulminant Myocarditis with Combination Immune Checkpoint Blockade N Engl J Med, 2016.PMID 27806233
- [3]D'Gama JD, Bermas BL Safety of biologic agents for the management of rheumatic diseases during pregnancy Curr Opin Rheumatol, 2024.PMID 38456470